| http://dbpedia.org/ontology/abstract
|
Asciminib ist ein Arzneistoff mit Wirkung … Asciminib ist ein Arzneistoff mit Wirkung aus der neuen Wirkstoffgruppe der STAMP-Hemmer. Er wurde im Oktober 2021 in den USA unter dem Namen Scemblix (Novartis) zugelassen zur oralen Behandlung der chronischen myeloischen Leukämie (CML) in der oder bei Vorliegen einer bestimmten Mutation im Philadelphia-Chromosom, im August 2022 folgte die Zulassung in der EU.ugust 2022 folgte die Zulassung in der EU.
, Asciminib, sold under the brand name Scemb … Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Asciminib is a protein kinase inhibitor. The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea. Asciminib was approved for medical use in the United States in October 2021, and in the European Union in August 2022. The U.S. Food and Drug Administration (FDA) granted the application for asciminib priority review, fast track, orphan drug, and breakthrough therapy designations.ug, and breakthrough therapy designations.
|
| http://dbpedia.org/ontology/alternativeName
|
Scemblix
|
| http://dbpedia.org/ontology/casNumber
|
2119669-71-3
, 1492952-76-7
|
| http://dbpedia.org/ontology/chEMBL
|
4208229
, 4297220
|
| http://dbpedia.org/ontology/class
|
http://dbpedia.org/resource/Tyrosine_kinase_inhibitor +
|
| http://dbpedia.org/ontology/drugbank
|
DB12597
|
| http://dbpedia.org/ontology/fdaUniiCode
|
C5U34S9XFV
, L1F3R18W77
|
| http://dbpedia.org/ontology/kegg
|
D11403
, D11404
|
| http://dbpedia.org/ontology/pubchem
|
72165228
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Asciminib.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/asciminib +
|
| http://dbpedia.org/ontology/wikiPageID
|
69148874
|
| http://dbpedia.org/ontology/wikiPageLength
|
15205
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1124401728
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Philadelphia_chromosome +
, http://dbpedia.org/resource/Myristoylation +
, http://dbpedia.org/resource/Allosteric +
, http://dbpedia.org/resource/Bcr-abl +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/Category:Breakthrough_therapy +
, http://dbpedia.org/resource/Active_site +
, http://dbpedia.org/resource/Tyrosine_kinase_inhibitor +
, http://dbpedia.org/resource/Protein_kinase_inhibitor +
, http://dbpedia.org/resource/Category:Novartis_brands +
, http://dbpedia.org/resource/Breakthrough_therapy +
, http://dbpedia.org/resource/Chronic_myeloid_leukemia +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/Category:Pyrrolidines +
, http://dbpedia.org/resource/N-terminus +
, http://dbpedia.org/resource/Category:Carboxamides +
, http://dbpedia.org/resource/Category:Pyridines +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Priority_review +
, http://dbpedia.org/resource/Category:Organochlorides +
, http://dbpedia.org/resource/Category:Pyrazoles +
, http://dbpedia.org/resource/Category:Difluoromethoxy_compounds +
, http://dbpedia.org/resource/Bcr-abl_inhibitor +
, http://dbpedia.org/resource/Committee_for_Medicinal_Products_for_Human_Use +
, http://dbpedia.org/resource/Fast_track_%28FDA%29 +
, http://dbpedia.org/resource/Orphan_drug +
, http://dbpedia.org/resource/Category:Non-receptor_tyrosine_kinase_inhibitors +
, http://dbpedia.org/resource/Ponatinib +
, http://dbpedia.org/resource/Medication +
|
| http://dbpedia.org/property/atcPrefix
|
L01
|
| http://dbpedia.org/property/atcSuffix
|
EA06
|
| http://dbpedia.org/property/c
|
20
|
| http://dbpedia.org/property/casNumber
|
1492952
, 2119669
|
| http://dbpedia.org/property/chembl
|
4297220
, 4208229
|
| http://dbpedia.org/property/chemspiderid
|
52085218
|
| http://dbpedia.org/property/cl
|
1
|
| http://dbpedia.org/property/class
|
http://dbpedia.org/resource/Tyrosine_kinase_inhibitor +
|
| http://dbpedia.org/property/dailymedid
|
Asciminib
|
| http://dbpedia.org/property/drugbank
|
DB12597
|
| http://dbpedia.org/property/f
|
2
|
| http://dbpedia.org/property/h
|
18
|
| http://dbpedia.org/property/index2Label
|
as HCl
|
| http://dbpedia.org/property/iupacName
|
N-4-[chloromethoxy]phenyl]-6-[-3-hydroxypyrrolidin-1-yl]-5-pyridine-3-carboxamide;hydrochloride
|
| http://dbpedia.org/property/iupharLigand
|
8962
|
| http://dbpedia.org/property/kegg
|
D11404
, D11403
|
| http://dbpedia.org/property/legalAu
|
S4
|
| http://dbpedia.org/property/legalCa
|
Rx-only
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/n
|
5
|
| http://dbpedia.org/property/o
|
3
|
| http://dbpedia.org/property/pdbLigand
|
AY7
|
| http://dbpedia.org/property/pregnancyAu
|
D
|
| http://dbpedia.org/property/pubchem
|
72165228
, 133082086
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/smiles
|
O=Cc1cnccc1
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
VOVZXURTCKPRDQ-CQSZACIVSA-N
|
| http://dbpedia.org/property/synonyms
|
ABL001
|
| http://dbpedia.org/property/tradename
|
Scemblix
|
| http://dbpedia.org/property/unii
|
L1F3R18W77
, C5U34S9XFV
|
| http://dbpedia.org/property/width
|
200
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:ClinicalTrialsGov +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Use_American_English +
, http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:Targeted_cancer_therapeutic_agents +
, http://dbpedia.org/resource/Template:Growth_factor_receptor_modulators +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Portal_bar +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Carboxamides +
, http://dbpedia.org/resource/Category:Pyrazoles +
, http://dbpedia.org/resource/Category:Novartis_brands +
, http://dbpedia.org/resource/Category:Difluoromethoxy_compounds +
, http://dbpedia.org/resource/Category:Breakthrough_therapy +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/Category:Pyrrolidines +
, http://dbpedia.org/resource/Category:Pyridines +
, http://dbpedia.org/resource/Category:Non-receptor_tyrosine_kinase_inhibitors +
, http://dbpedia.org/resource/Category:Organochlorides +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Asciminib?oldid=1124401728&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Asciminib.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Asciminib +
|
| owl:sameAs |
http://de.dbpedia.org/resource/Asciminib +
, https://global.dbpedia.org/id/2Xymp +
, http://dbpedia.org/resource/Asciminib +
, http://www.wikidata.org/entity/Q27074535 +
|
| rdf:type |
http://dbpedia.org/ontology/ChemicalSubstance +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/ontology/Drug +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
|
| rdfs:comment |
Asciminib, sold under the brand name Scemb … Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Asciminib is a protein kinase inhibitor. The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea. Asciminib was approved for medical use in the United States in October 2021, and in the European Union in August 2022. and in the European Union in August 2022.
, Asciminib ist ein Arzneistoff mit Wirkung … Asciminib ist ein Arzneistoff mit Wirkung aus der neuen Wirkstoffgruppe der STAMP-Hemmer. Er wurde im Oktober 2021 in den USA unter dem Namen Scemblix (Novartis) zugelassen zur oralen Behandlung der chronischen myeloischen Leukämie (CML) in der oder bei Vorliegen einer bestimmten Mutation im Philadelphia-Chromosom, im August 2022 folgte die Zulassung in der EU.ugust 2022 folgte die Zulassung in der EU.
|
| rdfs:label |
Asciminib
|
